News

The phase III SOLO-2 trial randomized 295 patients with documented germline BRCA1 or BRCA2 mutations who had received at least two prior lines of platinum-based chemotherapy. It showed

The company signed an agreement with the US Food and Drug Administration (FDA) regarding the trial’s design. The phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS

SCD is the most common inherited blood disorder in the United States and is caused by a genetic mutation that results in the production of abnormal hemoglobin, the

Vanda has entered into a License Agreement (the License Agreement) with Taro Pharmaceuticals U.S.A., Inc. and Taro Pharmaceutical Industries Ltd. (collectively, Taro) to resolve Vanda's patent litigation against

The company submitted a biologics licence application (BLA) to the US Food and Drug Administration (FDA) to market the vaccine for the prevention of herpes zoster (shingles) in

The phase 3 Keynote-045 trial demonstrated that Keytruda was superior compared to investigator choice chemotherapy. The drug’s safety profile was consistent with that observed in earlier reported trials

Faron has also recently received the second IDMC (Independent Data Monitoring Committee) recommendation to continue the INTEREST pan-European Phase III trial with Traumakine without any modifications. ARDS is

The first drug candidate within the expanded scope, (CAM2058), is an extended release injectable combination of buprenorphine and granisetron in the FluidCrystal® injection depot technology. CAM2058 has completed

One study showed that people with VTE taking XARELTO® for longer than three months had a lower risk of VTE recurrence, without an increase in major bleeding, compared